finnCap, a leading independent broker to ambitious companies, today announces the appointment of Mark Brewer as Senior Life Sciences Analyst to its Research team.
Mark has 28 years of experience in the City, starting as a UK Pharmaceutical and Healthcare analyst at Credit Lyonnais Securities, before working as an analyst at ABN Amro, Dresdner Kleinwort Wassertein, Satellite Asset Management, Eden Financial and Hardman & Co.
Mark will work alongside Keith Redpath, who is being retained as a consultant to finnCap.
Sam Smith, CEO of finnCap, said:
“We are delighted to welcome Mark to finnCap. The Life Sciences sector is very important to finnCap and we are currently ranked as the leading adviser to healthcare companies on AIM. I am confident that Mark will be a real asset in driving this part of the business forwards.”